Posted by Michael Wonder on 03 Mar 2018
Otonomy announces FDA approval of Otiprio for acute otitis externa
2 March 2018 - Otonomy today announced that the U.S. FDA has approved Otiprio (ciprofloxacin 6% otic suspension) for the treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
Otiprio is the first single-dose anti-bacterial approved by the FDA for treating acute otitis media.
